🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07443202
Enrolling by invitation Phase 2

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

NCT07443202 · tracked via the Priya Life Science USA tracker
Sponsor
Tarsus Pharmaceuticals, Inc.
Phase
Phase 2
Started
2025-12-05
Last updated
2026-03-02

Condition(s) studied

Ocular Rosacea

Investigational drug(s) / intervention(s)

lotilanerVehicle

lotilaner: lotilaner

Vehicle: Vehicle of lotilaner

Study summary

To evaluate lotilaner treatment in patients with ocular rosacea.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older at the time of consent. * Has moderate to severe ocular rosacea * Use of acceptable methods of contraception * Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol Exclusion Criteria: * Patient taking a topical or other therapy which may affect the patients rosacea * Actively managed glaucoma or active ocular infection or ocular systemic disease * Have hypersensitivity to lotilaner or any of the formulation components * Are currently enrolled in an investigational drug or device study * Are currently pregnant or lactating or planning to become pregnant during the study

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Site Houston Texas
Site Lynchburg Virginia

More Tarsus Pharmaceuticals, Inc. trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07443202 on ClinicalTrials.gov ↗ ← All trials in the USA